<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573155</url>
  </required_header>
  <id_info>
    <org_study_id>D6640C00001</org_study_id>
    <secondary_id>2015-002906-36</secondary_id>
    <nct_id>NCT02573155</nct_id>
  </id_info>
  <brief_title>Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects</brief_title>
  <official_title>A 2-part, Randomised, Placebo-controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of AZD8871 Delivered by Inhalation in Asthmatic and Chronic Obstructive Pulmonary Disease (COPD) Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, randomised, placebo-controlled 2-part study to assess the safety,
      tolerability, pharmacokinetics and pharmacodynamics of AZD8871 delivered by inhalation, in
      asthmatic and chronic obstructive pulmonary disease (COPD) subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an integrated Phase I protocol divided into 2 parts.

      Part 1: single ascending dose study (6 AZD8871 dose levels) in 16 male subjects with mild
      asthma. AZD8871 will be administered (by the Genuair® inhaler) under supervision at the study
      centre, according to the randomisation scheme

      Part 2: a 5 treatment period single dose study (of AZD8871 [two doses], indacaterol,
      tiotropium and placebo) in 40 male and non-childbearing female subjects with moderate to
      severe COPD. Each treatment period will be separated by a washout period of at least 7 days.
      The primary comparison for bronchodilation will be between AZD8871 doses and placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants With Mild Persistent Asthma (Part 1) and COPD (Part 2) With at Least 1 Treatment-emergent Adverse Event</measure>
    <time_frame>From the time of informed consent up to 14 (±2) days after the last dose of investigational product. Unresolved AEs were followed up by the investigator for as long as medically indicated.</time_frame>
    <description>An adverse event is the development of an undesirable medical condition, or the deterioration of a pre-existing medical condition, following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms, signs, or the abnormal results of laboratory parameters (haematology, blood chemistry, urinalysis, physical examination, 12-lead ECGs and telemetry, and vital signs). AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 18.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Relevant Abnormalities in Blood Pressure</measure>
    <time_frame>From the time of informed consent up to 36 hours after last dose of IP.</time_frame>
    <description>Blood pressure (BP) measurements (diastolic [DBP] and systolic BP [SBP]) taken after ~5 minutes rest in supine position, at screening, baseline (≤1 hour before IP administration), 10 and 30 minutes, 1, 2, 3, 4, 8, 12 hours (Day 1) and 24 and 36 hours (Day 2) after IP administration. Normal BP at screening: SBP 100-140 mmHg (subjects aged ≤59 years) and 100-150 mmHg (subjects aged ≥60 years), and DBP 40-90 mmHg.
Criteria for notable changes in BP:
High SBP: (≥180 and increase over baseline (predose) ≥20) or (≥200 and baseline &lt;200) Low SBP: (≤ 90 and decrease over baseline ≥20) or (≤75 and baseline &gt;75) High DBP: (≥105 and increase over baseline ≥15) or (≥115 and baseline &lt;115) Low DBP: (≤50 and decrease over baseline ≥15) or (≤40 and baseline &gt;40) All out of range values were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until considered non-clinically relevant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Relevant Abnormalities in Electrocardiograms (HR, QTcF and Other ECG Parameters).</measure>
    <time_frame>From the time of informed consent up to 36 hours after last dose of IP.</time_frame>
    <description>HR, QTcF and other ECG abnormalities were assessed by local digital 12-lead ECG performed in triplicate at the time points indicated:
ECG (Parts 1 and 2) was assessed at Screening, Day 1 baseline, 10 min, 30 min, 1 hour (h), 2 h, 3 h, 4 h, 8 h, 12 h, 24 h, 36 h after dosing.
Telemetry (Part 1), assessed with at least 2 lead real time display, was recorded at Day -1 (4-6 hours continuous recording, at the time this was more convenient for the logistics of the unit) and on Day 1 from the time of the IP administration up to at least 24 hours, but if advised by the Investigator or designee, then up to 36 hours after IP administration.
Abnormal findings were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until the abnormality was considered non-clinically relevant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Relevant Abnormalities in Clinical Biochemistry, Hematology and Urinalysis</measure>
    <time_frame>From the time of informed consent up to 7 days after the last dose of IP.</time_frame>
    <description>A composite of clinically relevant abnormalities in clinical biochemistry, hematology and urinalysis laboratory evaluations. Laboratory tests (haematology, blood chemistry, and urinalysis) were performed at screening, at Day -1 (Part 1 only), at 24 hours (Day 2) and at follow-up (7 [±2] days) after IP administration. Coagulation was only performed at screening; TSH, T4 only at screening, at Day-1 and at follow-up.
Abnormal findings were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until the abnormality was considered non-clinically relevant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) on Day 2</measure>
    <time_frame>Baseline (Day 1) to 36 hours post-dose (Day 2)</time_frame>
    <description>Pharmacodynamics of AZD8871 before (-45 min and -15 min pre-dose) and after single dosing of AZD8871 Forced expiratory volume in 1 second (FEV1) on Day 2 (defined as the average of the values 23:00 and 24:00 hours after the morning dose of investigational product)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of AZD8871 in Parts 1 and 2</measure>
    <time_frame>Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose</time_frame>
    <description>Cmax (maximum observed plasma drug concentrations) of AZD8871 on Day 1 of each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of AZD8871 in Parts 1 and 2</measure>
    <time_frame>Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose</time_frame>
    <description>tmax (time to reach maximum concentration) of AZD8871 on Day 1 of each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t) of AZD8871 in Parts 1 and 2</measure>
    <time_frame>Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose</time_frame>
    <description>AUC(0-t) (area under the concentration-time curve from time zero to time of the last quantifiable measurable concentration) of AZD8871 on Day 1 of each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24) of AZD8871 in Parts 1 and 2</measure>
    <time_frame>Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose</time_frame>
    <description>AUC(0-24) (area under the concentration-time curve from zero to 24h) of AZD8871 on Day 1 of each treatment period.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AUC of AZD8871 in Parts 1 and 2</measure>
    <time_frame>Predose, and 5 min, 15 min, 30 min, and 45 min, at 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h and 36 h (Day 2) post-dose</time_frame>
    <description>AUC (area under the concentration-time curve from time 0 to infinity) of AZD8871 on Day 1 of each treatment period</description>
  </other_outcome>
  <other_outcome>
    <measure>Elimination Half-life of AZD8871 in Parts 1 and 2</measure>
    <time_frame>Predose, and 5 min, 15 min, 30 min, and 45 min, at 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h and 36 h (Day 2) post-dose</time_frame>
    <description>Elimination half-life (t½λz) for AZD8871 on Day 1 of each treatment period. t½λz was generally calculated over a period of less than 3 times the resultant half-life</description>
  </other_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Asthma (Part 1)</condition>
  <condition>COPD (Part 2)</condition>
  <arm_group>
    <arm_group_label>Sequence 1, Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Dose 1 Period 2: Dose 3 Period 3: Dose 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2, Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Placebo Period 2: Dose 3 Period 3: Dose 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3, Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Dose 1 Period 2: Placebo Period 3: Dose 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4, Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Dose 1 Period 2: Dose 3 Period 3: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5, Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Dose 2 Period 2: Dose 4 Period 3: Dose 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6, Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Placebo Period 2: Dose 4 Period 3: Dose 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 7, Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Dose 2 Period 2: Placebo Period 3: Dose 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 8, Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Dose 2 Period 2: Dose 4 Period 3: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 1, Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment A Period 2: Treatment B Period 3: Treatment E Period 4: Treatment C Period 5: Treatment D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2, Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment B Period 2: Treatment C Period 3: Treatment A Period 4: Treatment D Period 5: Treatment E</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3, Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment C Period 2: Treatment D Period 3: Treatment B Period 4: Treatment E Period 5: Treatment A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4, Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment D Period 2: Treatment E Period 3: Treatment C Period 4: Treatment A Period 5: Treatment B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5, Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment E Period 2: Treatment A Period 3: Treatment D Period 4: Treatment B Period 5: Treatment C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6, Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment D Period 2: Treatment C Period 3: Treatment E Period 4: Treatment B Period 5: Treatment A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 7, Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment E Period 2: Treatment D Period 3: Treatment A Period 4: Treatment C Period 5: Treatment B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 8, Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment A Period 2: Treatment E Period 3: Treatment B Period 4: Treatment D Period 5: Treatment C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 9, Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment B Period 2: Treatment A Period 3: Treatment C Period 4: Treatment E Period 5: Treatment D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 10, Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment C Period 2: Treatment B Period 3: Treatment D Period 4: Treatment A Period 5: Treatment E</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 1, AZD8871 50 μg (Part 1)</intervention_name>
    <description>50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)</description>
    <arm_group_label>Sequence 1, Part 1</arm_group_label>
    <arm_group_label>Sequence 3, Part 1</arm_group_label>
    <arm_group_label>Sequence 4, Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 2, AZD8871 100 μg (Part 1)</intervention_name>
    <description>100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)</description>
    <arm_group_label>Sequence 5, Part 1</arm_group_label>
    <arm_group_label>Sequence 7, Part 1</arm_group_label>
    <arm_group_label>Sequence 8, Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 3, AZD8871 300 μg (Part 1)</intervention_name>
    <description>300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)</description>
    <arm_group_label>Sequence 1, Part 1</arm_group_label>
    <arm_group_label>Sequence 2, Part 1</arm_group_label>
    <arm_group_label>Sequence 4, Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 4, AZD8871 600 µg (Part 1)</intervention_name>
    <description>600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)</description>
    <arm_group_label>Sequence 5, Part 1</arm_group_label>
    <arm_group_label>Sequence 6, Part 1</arm_group_label>
    <arm_group_label>Sequence 8, Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 5, AZD8871 1200 µg (Part 1)</intervention_name>
    <description>1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)</description>
    <arm_group_label>Sequence 1, Part 1</arm_group_label>
    <arm_group_label>Sequence 2, Part 1</arm_group_label>
    <arm_group_label>Sequence 3, Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 6, AZD8871 1800 μg (Part 1)</intervention_name>
    <description>1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)</description>
    <arm_group_label>Sequence 5, Part 1</arm_group_label>
    <arm_group_label>Sequence 6, Part 1</arm_group_label>
    <arm_group_label>Sequence 7, Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, AZD8871 placebo (Part 1)</intervention_name>
    <description>AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)</description>
    <arm_group_label>Sequence 2, Part 1</arm_group_label>
    <arm_group_label>Sequence 3, Part 1</arm_group_label>
    <arm_group_label>Sequence 4, Part 1</arm_group_label>
    <arm_group_label>Sequence 6, Part 1</arm_group_label>
    <arm_group_label>Sequence 7, Part 1</arm_group_label>
    <arm_group_label>Sequence 8, Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A, AZD8871 dose A (Part 2)</intervention_name>
    <description>AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)</description>
    <arm_group_label>Sequence 1, Part 2</arm_group_label>
    <arm_group_label>Sequence 10, Part 2</arm_group_label>
    <arm_group_label>Sequence 2, Part 2</arm_group_label>
    <arm_group_label>Sequence 3, Part 2</arm_group_label>
    <arm_group_label>Sequence 4, Part 2</arm_group_label>
    <arm_group_label>Sequence 5, Part 2</arm_group_label>
    <arm_group_label>Sequence 6, Part 2</arm_group_label>
    <arm_group_label>Sequence 7, Part 2</arm_group_label>
    <arm_group_label>Sequence 8, Part 2</arm_group_label>
    <arm_group_label>Sequence 9, Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B, AZD8871 dose B (Part 2)</intervention_name>
    <description>AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)</description>
    <arm_group_label>Sequence 1, Part 2</arm_group_label>
    <arm_group_label>Sequence 10, Part 2</arm_group_label>
    <arm_group_label>Sequence 2, Part 2</arm_group_label>
    <arm_group_label>Sequence 3, Part 2</arm_group_label>
    <arm_group_label>Sequence 4, Part 2</arm_group_label>
    <arm_group_label>Sequence 5, Part 2</arm_group_label>
    <arm_group_label>Sequence 6, Part 2</arm_group_label>
    <arm_group_label>Sequence 7, Part 2</arm_group_label>
    <arm_group_label>Sequence 8, Part 2</arm_group_label>
    <arm_group_label>Sequence 9, Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C, Indacaterol 150 μg (Part 2)</intervention_name>
    <description>150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule</description>
    <arm_group_label>Sequence 1, Part 2</arm_group_label>
    <arm_group_label>Sequence 10, Part 2</arm_group_label>
    <arm_group_label>Sequence 2, Part 2</arm_group_label>
    <arm_group_label>Sequence 3, Part 2</arm_group_label>
    <arm_group_label>Sequence 4, Part 2</arm_group_label>
    <arm_group_label>Sequence 5, Part 2</arm_group_label>
    <arm_group_label>Sequence 6, Part 2</arm_group_label>
    <arm_group_label>Sequence 7, Part 2</arm_group_label>
    <arm_group_label>Sequence 8, Part 2</arm_group_label>
    <arm_group_label>Sequence 9, Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment D, Tiotropium 18 μg (Part 2)</intervention_name>
    <description>18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule</description>
    <arm_group_label>Sequence 1, Part 2</arm_group_label>
    <arm_group_label>Sequence 10, Part 2</arm_group_label>
    <arm_group_label>Sequence 2, Part 2</arm_group_label>
    <arm_group_label>Sequence 3, Part 2</arm_group_label>
    <arm_group_label>Sequence 4, Part 2</arm_group_label>
    <arm_group_label>Sequence 5, Part 2</arm_group_label>
    <arm_group_label>Sequence 6, Part 2</arm_group_label>
    <arm_group_label>Sequence 7, Part 2</arm_group_label>
    <arm_group_label>Sequence 8, Part 2</arm_group_label>
    <arm_group_label>Sequence 9, Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Part 1

          1. Subjects who are able and willing to provide written informed consent prior to
             conducting any study-related procedures, including withdrawal of medications

          2. Adult male subjects aged 18 to 70 years (both inclusive)

          3. Body mass index (BMI) from 18 to 32 kg/m2 at screening

          4. Clinical diagnosis of asthma (according to the Global Initiative for Asthma [GINA]
             guidelines) for at least 6 months prior to screening

          5. Ability to change current asthma therapy, to discontinue previous prescribed
             medications after signature of informed consent as per required washout periods

          6. Screening FEV1 value of ≥70% of the predicted normal value

          7. FEV1 reversibility of ≥12% and an absolute increase of at least 200 mL over the
             baseline value within 30 min after inhalation of 400 µg (4 puffs) of salbutamol via a
             metered dose inhaler, with spacer device

          8. Subjects using intermittent salbutamol and / or subjects on a stable dose of low dose
             Inhaled corticosteroid (as defined by the GINA guidelines) at least 4 weeks prior to
             screening

          9. Predose FEV1 value of first treatment period within the range of ± 20% of the FEV1
             measured at screening prior to salbutamol inhalation

         10. No current smokers, no subjects with a smoking history during the last 12 months and
             no subjects with a total smoking history of more than 10 pack-years

         11. No other relevant pulmonary disease or history of thoracic surgery

         12. Subjects who are otherwise healthy as determined by medical history, physical
             examination, 12-lead ECG findings

         13. Normal blood pressure (defined as Systolic blood pressure [SBP] between 100 and 140
             mmHg for subjects ≤59 years of age and between 100 and 150 mmHg for subjects ≥60 years
             of age, and Diastolic blood pressure [DBP] between 40 and 90 mmHg) at screening

         14. Subjects whose clinical laboratory test results are not clinically relevant and are
             acceptable to the Investigator.

         15. Subjects who are negative for hepatitis B surface antigen (HBsAg), hepatitis B core
             (HBc) antibody (IgM), hepatitis C antibody and human immunodeficiency virus (HIV) I
             and II antibodies at screening

         16. Subjects who are negative for drugs of abuse and alcohol tests at screening and
             admission

         17. Subjects able to perform repeatable pulmonary function testing for FEV1 according to
             the American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005(9)
             criteria at screening

        Inclusion Criteria: Part 2

          1. Adult male and non-childbearing female subjects aged ≥40 years with a clinical
             diagnosis of stable moderate to severe COPD according to GOLD guidelines at screening

          2. Females must be of non-childbearing potential, confirmed at screening by fulfilling
             study predefined criteria

          3. Post-salbutamol FEV1 &lt;80% and ≥30% of the predicted normal value and post-salbutamol
             FEV1 / forced vital capacity (FVC) &lt;70%

          4. BMI &lt; 40 kg/m2 at screening

          5. Ability to change current COPD therapy, to discontinue previous prescribed medications
             after signature of informed consent as per required washout periods

          6. Current or ex-smokers with a smoking history of ≥10 pack years

          7. No evidence of clinically significant respiratory and / or cardiovascular conditions
             (e.g. uncontrolled hypertension) or laboratory abnormalities

          8. No other relevant pulmonary disease or history of thoracic surgery

          9. Subjects who are negative for HBsAg, HBc IgM, hepatitis C antibody and HIV I and II
             antibodies at screening

         10. Subjects who are able and willing to provide written informed consent prior to
             conducting any study-related procedures, including withdrawal of medications

         11. Medical history must be verified by either a personal physician or medical
             practitioner as appropriate

         12. Subjects able to perform repeatable pulmonary function testing for FEV1 according to
             the ATS / ERS 2005(9) criteria at screening

        Exclusion Criteria (Part 1 &amp; 2):

          1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff and/or staff at the study site)

          2. Previous enrolment or randomisation of treatment in the present study

          3. Current evidence or recent history of any clinically significant and unstable disease
             (other than asthma/COPD) or abnormality that could put the subject at risk or could
             confound the results of the study

          4. Subjects with a surgical history clinically relevant for the purpose of the study

          5. History of malignancy of any organ system, treated or untreated within the past 5
             years, with the exception of localised basal cell carcinoma of the skin

          6. Subjects with serious adverse reaction or serious hypersensitivity to Tiotropium (for
             Part 2 only), Indacaterol (for Part 2 only), or the formulation excipients (eg,
             lactose) or other drugs in the same pharmacologic class (for Part 1 and Part 2)

          7. Current diagnosis of COPD (for Part 1 only) or history of / or current diagnosis for
             asthma (for Part 2 only)

          8. Recent history of asthma / COPD exacerbation requiring hospitalisation or need for
             increased maintenance treatments for asthma / COPD within 6 weeks prior to screening
             or prior to randomisation

          9. Use of daily oxygen therapy &gt;10 h per day (for Part 2 only)

         10. Use of systemic steroids for respiratory reasons within 6 weeks prior to screening

         11. Lower respiratory tract infection within 6 weeks prior to screening or prior to
             randomisation

         12. Upper respiratory tract infection requiring antibiotics within 6 weeks prior to
             screening or prior to randomisation

         13. Current history of tuberculosis, bronchiectasis or other non-specific pulmonary
             disease

         14. Subject with significant cardiovascular disease that may be vulnerable to
             cardiovascular instability

         15. QTcF (QT interval corrected, Fridericia formula QT[msec]/RR[s]) interval, &gt;450 ms for
             males and &gt;470 ms for females at screening or prior to randomisation, or history of
             long QT syndrome

         16. PR (duration in milliseconds from the beginning of wave P to onset of ventricular
             depolarisation [Q or R]) interval &gt;200 ms at screening or prior to randomisation (for
             Part 1 only) Note: 4- 6 hours of ECG rhythm monitoring with telemetry will be
             performed on Day-1 to identify patients that may have any clinical significant
             abnormality prior to randomisation. If this occurs, patients should not participate in
             the study

         17. Subjects with serum potassium concentration &lt; 3.5mmol/l at screening

         18. Subjects with a history of excessive use or abuse of alcohol within the past 2 years

         19. Subjects with a history of drug abuse within the past 2 years

         20. Subjects who are positive for drugs of abuse and alcohol tests at screening and prior
             to randomisation. Subjects consuming more than 14 (female subjects) or 21 (male
             subjects) units of alcohol a week

         21. Donation or loss &gt;400 ml of blood and plasma within the previous 3 months prior to
             screening

         22. Subjects with a significant infection or known inflammatory process at screening or
             prior to randomisation

         23. Subjects with acute gastrointestinal symptoms at the time of screening or prior to
             randomisation (eg, nausea, vomiting, diarrhoea, heartburn)

         24. Subjects with an acute infection such as influenza at the time of screening or prior
             to randomisation

         25. Male subjects who do not agree to follow instructions to avoid pregnancies

         26. Subjects who are not able to adhere to the restrictions on prior and concomitant
             medications

         27. Subjects who intend to use any concomitant medication not permitted by this protocol
             or who have not undergone the required washout period for a particular prohibited
             medication

         28. Subjects who have used any investigational drug within 3 months prior to screening or
             within the equivalent time of 6 half-lives of receiving the last administration,
             whichever is longer

         29. Subjects who have received the last dose of investigational product more than 3 months
             ago but who are on an extended follow-up

         30. Subjects who are unlikely to co-operate with the requirements of the study, or the
             study center or the subjects who are unwilling or unable to follow the instructions of
             the principal investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muna Albayaty, MBChB, MSc,MFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Early Phase Clinical Unit, London, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dave Singh, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Medicines Evaluation Unit (MEU), Manchester, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>October 8, 2015</study_first_submitted>
  <study_first_submitted_qc>October 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <results_first_submitted>August 22, 2017</results_first_submitted>
  <results_first_submitted_qc>April 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2018</results_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>AZD8871</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>mild persistent asthma</keyword>
  <keyword>moderate to severe COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 2 centres in the UK (one for each part). In part 1 of the study, the first patient was screened in October 2015 and the last patient visit was in March 2016. In part 2 of the study, the first patient was screened in April 2016 and the last patient visit was in August 2016.</recruitment_details>
      <pre_assignment_details>2-part study: Part 1: single ascending doses of AZD8871 (planned 50, 100, 300, 600, 1200, 1800 μg; actual dose 50, 200, 400, 900, 1800, 2100 μg) or placebo over 3 treatment periods; 2 cohorts (male; mild persistent asthma).
Part 2: 5-way complete cross-over, single-dose; M/F, moderate/severe COPD; 2 doses of AZD8871, placebo, or 2 active controls.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Population - Part 1</title>
          <description>All individuals in Part 1 (patients who received single doses of AZD8871 [50, 400, 1800 μg for Cohort 1; 200, 900, 2100 μg for Cohort 2], or placebo, in 3 treatment periods separated by washout periods of 14 days).</description>
        </group>
        <group group_id="P2">
          <title>Overall Population - Part 2</title>
          <description>All individuals involved in Part 2 (patients who received single doses of AZD8871 [400 and 1800 μg], placebo, indacaterol 150 μg, or tiotropium 18 μg, in 5 treatment periods separated by washout periods of 7-21 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Between Treatment Period 1 and 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Between Treatment Period 2 and 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor's decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Between Treatment Period 3 and 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Part 1 comprised 3 treatment periods only</participants>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Part 1 comprised 3 treatment periods only</participants>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Stability/variability criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Part 1 comprised 3 treatment periods only</participants>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Part 1 comprised 3 treatment periods only</participants>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Between Treatment Period 4 and 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Part 1 comprised 3 treatment periods only</participants>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Part 1 comprised 3 treatment periods only</participants>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Part 1 comprised 3 treatment periods only</participants>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Part 1 comprised 3 treatment periods only</participants>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects who received at least 1 dose of the investigational product in Parts 1 and 2, respectively.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Population - Part 1</title>
          <description>All individuals in Part 1 (patients who received single doses of AZD8871 [50, 400, 1800 μg for Cohort 1; 200, 900, 2100 μg for Cohort 2], or placebo, in 3 treatment periods separated by washout periods of 14 days).</description>
        </group>
        <group group_id="B2">
          <title>Overall Population - Part 2</title>
          <description>All individuals involved in Part 2 (patients who received single doses of AZD8871 [400 and 1800 μg], placebo, indacaterol 150 μg, or tiotropium 18 μg, in 5 treatment periods separated by washout periods of 7-21 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.0" spread="11.8"/>
                    <measurement group_id="B2" value="65.6" spread="6.4"/>
                    <measurement group_id="B3" value="NA" spread="NA">Combined baseline demographic data were not calculated for Parts 1 and 2 of the study, which included separate patient populations (NA)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With Mild Persistent Asthma (Part 1) and COPD (Part 2) With at Least 1 Treatment-emergent Adverse Event</title>
        <description>An adverse event is the development of an undesirable medical condition, or the deterioration of a pre-existing medical condition, following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms, signs, or the abnormal results of laboratory parameters (haematology, blood chemistry, urinalysis, physical examination, 12-lead ECGs and telemetry, and vital signs). AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 18.1.</description>
        <time_frame>From the time of informed consent up to 14 (±2) days after the last dose of investigational product. Unresolved AEs were followed up by the investigator for as long as medically indicated.</time_frame>
        <population>Safety population: all randomized subjects who received at least 1 dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8871 50 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O2">
            <title>AZD8871 200 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O3">
            <title>AZD8871 400 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O4">
            <title>AZD8871 900 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O5">
            <title>AZD8871 1800 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O6">
            <title>AZD8871 2100 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O8">
            <title>AZD8871 400 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O9">
            <title>AZD8871 1800 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O10">
            <title>Indacaterol 150 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Onbrez Breezhaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O11">
            <title>Tiotropium 18 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by HandiHaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O12">
            <title>Placebo (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Mild Persistent Asthma (Part 1) and COPD (Part 2) With at Least 1 Treatment-emergent Adverse Event</title>
          <description>An adverse event is the development of an undesirable medical condition, or the deterioration of a pre-existing medical condition, following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms, signs, or the abnormal results of laboratory parameters (haematology, blood chemistry, urinalysis, physical examination, 12-lead ECGs and telemetry, and vital signs). AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 18.1.</description>
          <population>Safety population: all randomized subjects who received at least 1 dose of the investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="32"/>
                <count group_id="O11" value="30"/>
                <count group_id="O12" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="12"/>
                    <measurement group_id="O11" value="11"/>
                    <measurement group_id="O12" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Relevant Abnormalities in Blood Pressure</title>
        <description>Blood pressure (BP) measurements (diastolic [DBP] and systolic BP [SBP]) taken after ~5 minutes rest in supine position, at screening, baseline (≤1 hour before IP administration), 10 and 30 minutes, 1, 2, 3, 4, 8, 12 hours (Day 1) and 24 and 36 hours (Day 2) after IP administration. Normal BP at screening: SBP 100-140 mmHg (subjects aged ≤59 years) and 100-150 mmHg (subjects aged ≥60 years), and DBP 40-90 mmHg.
Criteria for notable changes in BP:
High SBP: (≥180 and increase over baseline (predose) ≥20) or (≥200 and baseline &lt;200) Low SBP: (≤ 90 and decrease over baseline ≥20) or (≤75 and baseline &gt;75) High DBP: (≥105 and increase over baseline ≥15) or (≥115 and baseline &lt;115) Low DBP: (≤50 and decrease over baseline ≥15) or (≤40 and baseline &gt;40) All out of range values were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until considered non-clinically relevant.</description>
        <time_frame>From the time of informed consent up to 36 hours after last dose of IP.</time_frame>
        <population>Safety population: all randomized subjects who received at least 1 dose of the investigational product</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8871 50 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O2">
            <title>AZD8871 200 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O3">
            <title>AZD8871 400 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O4">
            <title>AZD8871 900 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O5">
            <title>AZD8871 1800 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O6">
            <title>AZD8871 2100 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O8">
            <title>AZD8871 400 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O9">
            <title>AZD8871 1800 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O10">
            <title>Indacaterol 150 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Onbrez Breezhaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O11">
            <title>Tiotropium 18 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by HandiHaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O12">
            <title>Placebo (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Abnormalities in Blood Pressure</title>
          <description>Blood pressure (BP) measurements (diastolic [DBP] and systolic BP [SBP]) taken after ~5 minutes rest in supine position, at screening, baseline (≤1 hour before IP administration), 10 and 30 minutes, 1, 2, 3, 4, 8, 12 hours (Day 1) and 24 and 36 hours (Day 2) after IP administration. Normal BP at screening: SBP 100-140 mmHg (subjects aged ≤59 years) and 100-150 mmHg (subjects aged ≥60 years), and DBP 40-90 mmHg.
Criteria for notable changes in BP:
High SBP: (≥180 and increase over baseline (predose) ≥20) or (≥200 and baseline &lt;200) Low SBP: (≤ 90 and decrease over baseline ≥20) or (≤75 and baseline &gt;75) High DBP: (≥105 and increase over baseline ≥15) or (≥115 and baseline &lt;115) Low DBP: (≤50 and decrease over baseline ≥15) or (≤40 and baseline &gt;40) All out of range values were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until considered non-clinically relevant.</description>
          <population>Safety population: all randomized subjects who received at least 1 dose of the investigational product</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="32"/>
                <count group_id="O11" value="30"/>
                <count group_id="O12" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="8.7"/>
                    <measurement group_id="O2" value="0" spread="2.1"/>
                    <measurement group_id="O3" value="0" spread="4.3"/>
                    <measurement group_id="O4" value="0" spread="7.2"/>
                    <measurement group_id="O5" value="0" spread="3.4"/>
                    <measurement group_id="O6" value="0" spread="11.7"/>
                    <measurement group_id="O7" value="0" spread="5.7"/>
                    <measurement group_id="O8" value="0" spread="8.3"/>
                    <measurement group_id="O9" value="0" spread="4.5"/>
                    <measurement group_id="O10" value="0" spread="6.3"/>
                    <measurement group_id="O11" value="0" spread="6.8"/>
                    <measurement group_id="O12" value="0" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Relevant Abnormalities in Electrocardiograms (HR, QTcF and Other ECG Parameters).</title>
        <description>HR, QTcF and other ECG abnormalities were assessed by local digital 12-lead ECG performed in triplicate at the time points indicated:
ECG (Parts 1 and 2) was assessed at Screening, Day 1 baseline, 10 min, 30 min, 1 hour (h), 2 h, 3 h, 4 h, 8 h, 12 h, 24 h, 36 h after dosing.
Telemetry (Part 1), assessed with at least 2 lead real time display, was recorded at Day -1 (4-6 hours continuous recording, at the time this was more convenient for the logistics of the unit) and on Day 1 from the time of the IP administration up to at least 24 hours, but if advised by the Investigator or designee, then up to 36 hours after IP administration.
Abnormal findings were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until the abnormality was considered non-clinically relevant.</description>
        <time_frame>From the time of informed consent up to 36 hours after last dose of IP.</time_frame>
        <population>Safety population: all randomized subjects who received at least 1 dose of the investigational product</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8871 50 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O2">
            <title>AZD8871 200 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O3">
            <title>AZD8871 400 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O4">
            <title>AZD8871 900 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O5">
            <title>AZD8871 1800 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O6">
            <title>AZD8871 2100 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O8">
            <title>AZD8871 400 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O9">
            <title>AZD8871 1800 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O10">
            <title>Indacaterol 150 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Onbrez Breezhaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O11">
            <title>Tiotropium 18 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by HandiHaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O12">
            <title>Placebo (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Abnormalities in Electrocardiograms (HR, QTcF and Other ECG Parameters).</title>
          <description>HR, QTcF and other ECG abnormalities were assessed by local digital 12-lead ECG performed in triplicate at the time points indicated:
ECG (Parts 1 and 2) was assessed at Screening, Day 1 baseline, 10 min, 30 min, 1 hour (h), 2 h, 3 h, 4 h, 8 h, 12 h, 24 h, 36 h after dosing.
Telemetry (Part 1), assessed with at least 2 lead real time display, was recorded at Day -1 (4-6 hours continuous recording, at the time this was more convenient for the logistics of the unit) and on Day 1 from the time of the IP administration up to at least 24 hours, but if advised by the Investigator or designee, then up to 36 hours after IP administration.
Abnormal findings were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until the abnormality was considered non-clinically relevant.</description>
          <population>Safety population: all randomized subjects who received at least 1 dose of the investigational product</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="32"/>
                <count group_id="O11" value="30"/>
                <count group_id="O12" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="4.5"/>
                    <measurement group_id="O2" value="0" spread="3.9"/>
                    <measurement group_id="O3" value="0" spread="3.7"/>
                    <measurement group_id="O4" value="0" spread="3.2"/>
                    <measurement group_id="O5" value="0" spread="5.2"/>
                    <measurement group_id="O6" value="0" spread="4.8"/>
                    <measurement group_id="O7" value="0" spread="6.2"/>
                    <measurement group_id="O8" value="0" spread="6.2"/>
                    <measurement group_id="O9" value="0" spread="7.7"/>
                    <measurement group_id="O10" value="0" spread="5.5"/>
                    <measurement group_id="O11" value="0" spread="4.7"/>
                    <measurement group_id="O12" value="0" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Relevant Abnormalities in Clinical Biochemistry, Hematology and Urinalysis</title>
        <description>A composite of clinically relevant abnormalities in clinical biochemistry, hematology and urinalysis laboratory evaluations. Laboratory tests (haematology, blood chemistry, and urinalysis) were performed at screening, at Day -1 (Part 1 only), at 24 hours (Day 2) and at follow-up (7 [±2] days) after IP administration. Coagulation was only performed at screening; TSH, T4 only at screening, at Day-1 and at follow-up.
Abnormal findings were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until the abnormality was considered non-clinically relevant.</description>
        <time_frame>From the time of informed consent up to 7 days after the last dose of IP.</time_frame>
        <population>Safety population: all randomized subjects who received at least 1 dose of the investigational product</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8871 50 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O2">
            <title>AZD8871 200 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O3">
            <title>AZD8871 400 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O4">
            <title>AZD8871 900 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O5">
            <title>AZD8871 1800 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O6">
            <title>AZD8871 2100 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O8">
            <title>AZD8871 400 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O9">
            <title>AZD8871 1800 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O10">
            <title>Indacaterol 150 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Onbrez Breezhaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O11">
            <title>Tiotropium 18 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by HandiHaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O12">
            <title>Placebo (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Abnormalities in Clinical Biochemistry, Hematology and Urinalysis</title>
          <description>A composite of clinically relevant abnormalities in clinical biochemistry, hematology and urinalysis laboratory evaluations. Laboratory tests (haematology, blood chemistry, and urinalysis) were performed at screening, at Day -1 (Part 1 only), at 24 hours (Day 2) and at follow-up (7 [±2] days) after IP administration. Coagulation was only performed at screening; TSH, T4 only at screening, at Day-1 and at follow-up.
Abnormal findings were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until the abnormality was considered non-clinically relevant.</description>
          <population>Safety population: all randomized subjects who received at least 1 dose of the investigational product</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="32"/>
                <count group_id="O11" value="30"/>
                <count group_id="O12" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) on Day 2</title>
        <description>Pharmacodynamics of AZD8871 before (-45 min and -15 min pre-dose) and after single dosing of AZD8871 Forced expiratory volume in 1 second (FEV1) on Day 2 (defined as the average of the values 23:00 and 24:00 hours after the morning dose of investigational product)</description>
        <time_frame>Baseline (Day 1) to 36 hours post-dose (Day 2)</time_frame>
        <population>The PP population is defined as all randomised subjects who satisfied the main I/E criteria, received IP, completed at least 1 treatment period, and did not present major violations to the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8871 50 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O2">
            <title>AZD8871 200 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O3">
            <title>AZD8871 400 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O4">
            <title>AZD8871 900 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O5">
            <title>AZD8871 1800 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O6">
            <title>AZD8871 2100 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O8">
            <title>AZD8871 400 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O9">
            <title>AZD8871 1800 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O10">
            <title>Indacaterol 150 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Onbrez Breezhaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O11">
            <title>Tiotropium 18 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by HandiHaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O12">
            <title>Placebo (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) on Day 2</title>
          <description>Pharmacodynamics of AZD8871 before (-45 min and -15 min pre-dose) and after single dosing of AZD8871 Forced expiratory volume in 1 second (FEV1) on Day 2 (defined as the average of the values 23:00 and 24:00 hours after the morning dose of investigational product)</description>
          <population>The PP population is defined as all randomised subjects who satisfied the main I/E criteria, received IP, completed at least 1 treatment period, and did not present major violations to the protocol</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="32"/>
                <count group_id="O11" value="30"/>
                <count group_id="O12" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0375" spread="0.3449"/>
                    <measurement group_id="O2" value="0.2183" spread="0.1631"/>
                    <measurement group_id="O3" value="0.2883" spread="0.1418"/>
                    <measurement group_id="O4" value="0.1858" spread="0.3528"/>
                    <measurement group_id="O5" value="0.3275" spread="0.0708"/>
                    <measurement group_id="O6" value="0.4630" spread="0.2065"/>
                    <measurement group_id="O7" value="-0.0600" spread="0.3099"/>
                    <measurement group_id="O8" value="0.0738" spread="0.1212"/>
                    <measurement group_id="O9" value="0.1731" spread="0.1761"/>
                    <measurement group_id="O10" value="0.1036" spread="0.1286"/>
                    <measurement group_id="O11" value="0.1055" spread="0.1922"/>
                    <measurement group_id="O12" value="-0.0294" spread="0.0768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean</param_type>
            <param_value>0.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0265</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0585</ci_lower_limit>
            <ci_upper_limit>0.163</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least square mean</param_type>
            <param_value>0.210</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0272</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.156</ci_lower_limit>
            <ci_upper_limit>0.264</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of AZD8871 in Parts 1 and 2</title>
        <description>Cmax (maximum observed plasma drug concentrations) of AZD8871 on Day 1 of each treatment period.</description>
        <time_frame>Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose</time_frame>
        <population>Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8871 50 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O2">
            <title>AZD8871 200 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O3">
            <title>AZD8871 400 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O4">
            <title>AZD8871 900 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O5">
            <title>AZD8871 1800 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O6">
            <title>AZD8871 2100 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O8">
            <title>AZD8871 400 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O9">
            <title>AZD8871 1800 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O10">
            <title>Indacaterol 150 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Onbrez Breezhaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O11">
            <title>Tiotropium 18 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by HandiHaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O12">
            <title>Placebo (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of AZD8871 in Parts 1 and 2</title>
          <description>Cmax (maximum observed plasma drug concentrations) of AZD8871 on Day 1 of each treatment period.</description>
          <population>Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.77" spread="60.77"/>
                    <measurement group_id="O2" value="174.1" spread="43.74"/>
                    <measurement group_id="O3" value="313.4" spread="46.56"/>
                    <measurement group_id="O4" value="797.3" spread="20.99"/>
                    <measurement group_id="O5" value="1351" spread="20.32"/>
                    <measurement group_id="O6" value="1243" spread="24.33"/>
                    <measurement group_id="O8" value="199.3" spread="37.40"/>
                    <measurement group_id="O9" value="810.8" spread="36.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of AZD8871 in Parts 1 and 2</title>
        <description>tmax (time to reach maximum concentration) of AZD8871 on Day 1 of each treatment period.</description>
        <time_frame>Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose</time_frame>
        <population>Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8871 50 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O2">
            <title>AZD8871 200 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O3">
            <title>AZD8871 400 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O4">
            <title>AZD8871 900 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O5">
            <title>AZD8871 1800 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O6">
            <title>AZD8871 2100 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O8">
            <title>AZD8871 400 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O9">
            <title>AZD8871 1800 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O10">
            <title>Indacaterol 150 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Onbrez Breezhaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O11">
            <title>Tiotropium 18 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by HandiHaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O12">
            <title>Placebo (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of AZD8871 in Parts 1 and 2</title>
          <description>tmax (time to reach maximum concentration) of AZD8871 on Day 1 of each treatment period.</description>
          <population>Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.52" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.86" lower_limit="0.48" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.75" upper_limit="1.05"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.98" upper_limit="1.02"/>
                    <measurement group_id="O5" value="1.49" lower_limit="0.73" upper_limit="2.03"/>
                    <measurement group_id="O6" value="1.02" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O8" value="1.00" lower_limit="0.75" upper_limit="3.00"/>
                    <measurement group_id="O9" value="2.00" lower_limit="0.75" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-t) of AZD8871 in Parts 1 and 2</title>
        <description>AUC(0-t) (area under the concentration-time curve from time zero to time of the last quantifiable measurable concentration) of AZD8871 on Day 1 of each treatment period.</description>
        <time_frame>Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose</time_frame>
        <population>Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8871 50 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O2">
            <title>AZD8871 200 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O3">
            <title>AZD8871 400 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O4">
            <title>AZD8871 900 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O5">
            <title>AZD8871 1800 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O6">
            <title>AZD8871 2100 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O8">
            <title>AZD8871 400 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O9">
            <title>AZD8871 1800 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O10">
            <title>Indacaterol 150 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Onbrez Breezhaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O11">
            <title>Tiotropium 18 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by HandiHaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O12">
            <title>Placebo (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-t) of AZD8871 in Parts 1 and 2</title>
          <description>AUC(0-t) (area under the concentration-time curve from time zero to time of the last quantifiable measurable concentration) of AZD8871 on Day 1 of each treatment period.</description>
          <population>Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="16"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110" spread="69.17"/>
                    <measurement group_id="O2" value="631.3" spread="30.40"/>
                    <measurement group_id="O3" value="1397" spread="31.41"/>
                    <measurement group_id="O4" value="3299" spread="27.00"/>
                    <measurement group_id="O5" value="6055" spread="24.98"/>
                    <measurement group_id="O6" value="6418" spread="35.13"/>
                    <measurement group_id="O8" value="1239" spread="37.70"/>
                    <measurement group_id="O9" value="6159" spread="44.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-24) of AZD8871 in Parts 1 and 2</title>
        <description>AUC(0-24) (area under the concentration-time curve from zero to 24h) of AZD8871 on Day 1 of each treatment period.</description>
        <time_frame>Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose</time_frame>
        <population>Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8871 50 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O2">
            <title>AZD8871 200 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O3">
            <title>AZD8871 400 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O4">
            <title>AZD8871 900 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O5">
            <title>AZD8871 1800 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O6">
            <title>AZD8871 2100 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O8">
            <title>AZD8871 400 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O9">
            <title>AZD8871 1800 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O10">
            <title>Indacaterol 150 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Onbrez Breezhaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O11">
            <title>Tiotropium 18 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by HandiHaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O12">
            <title>Placebo (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24) of AZD8871 in Parts 1 and 2</title>
          <description>AUC(0-24) (area under the concentration-time curve from zero to 24h) of AZD8871 on Day 1 of each treatment period.</description>
          <population>Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.9" spread="60.19"/>
                    <measurement group_id="O2" value="567.9" spread="29.74"/>
                    <measurement group_id="O3" value="1265" spread="32.44"/>
                    <measurement group_id="O4" value="3020" spread="25.71"/>
                    <measurement group_id="O5" value="5587" spread="25.40"/>
                    <measurement group_id="O6" value="5922" spread="34.32"/>
                    <measurement group_id="O8" value="1195" spread="38.91"/>
                    <measurement group_id="O9" value="5659" spread="43.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>AUC of AZD8871 in Parts 1 and 2</title>
        <description>AUC (area under the concentration-time curve from time 0 to infinity) of AZD8871 on Day 1 of each treatment period</description>
        <time_frame>Predose, and 5 min, 15 min, 30 min, and 45 min, at 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h and 36 h (Day 2) post-dose</time_frame>
        <population>Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8871 50 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O2">
            <title>AZD8871 200 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O3">
            <title>AZD8871 400 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O4">
            <title>AZD8871 900 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O5">
            <title>AZD8871 1800 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O6">
            <title>AZD8871 2100 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O8">
            <title>AZD8871 400 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O9">
            <title>AZD8871 1800 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O10">
            <title>Indacaterol 150 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Onbrez Breezhaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O11">
            <title>Tiotropium 18 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by HandiHaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O12">
            <title>Placebo (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of AZD8871 in Parts 1 and 2</title>
          <description>AUC (area under the concentration-time curve from time 0 to infinity) of AZD8871 on Day 1 of each treatment period</description>
          <population>Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.1" spread="75.48"/>
                    <measurement group_id="O2" value="774.5" spread="32.64"/>
                    <measurement group_id="O3" value="1671" spread="28.54"/>
                    <measurement group_id="O4" value="3831" spread="28.72"/>
                    <measurement group_id="O5" value="6941" spread="22.23"/>
                    <measurement group_id="O6" value="7164" spread="34.10"/>
                    <measurement group_id="O8" value="1459" spread="39.19"/>
                    <measurement group_id="O9" value="6769" spread="44.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Elimination Half-life of AZD8871 in Parts 1 and 2</title>
        <description>Elimination half-life (t½λz) for AZD8871 on Day 1 of each treatment period. t½λz was generally calculated over a period of less than 3 times the resultant half-life</description>
        <time_frame>Predose, and 5 min, 15 min, 30 min, and 45 min, at 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h and 36 h (Day 2) post-dose</time_frame>
        <population>Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8871 50 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O2">
            <title>AZD8871 200 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O3">
            <title>AZD8871 400 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O4">
            <title>AZD8871 900 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O5">
            <title>AZD8871 1800 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O6">
            <title>AZD8871 2100 μg (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Part 1)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O8">
            <title>AZD8871 400 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O9">
            <title>AZD8871 1800 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O10">
            <title>Indacaterol 150 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by Onbrez Breezhaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O11">
            <title>Tiotropium 18 μg (Part 2)</title>
            <description>Single-dose, oral inhalation by HandiHaler® single-dose dry powder inhaler (DPI)</description>
          </group>
          <group group_id="O12">
            <title>Placebo (Part 2)</title>
            <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life of AZD8871 in Parts 1 and 2</title>
          <description>Elimination half-life (t½λz) for AZD8871 on Day 1 of each treatment period. t½λz was generally calculated over a period of less than 3 times the resultant half-life</description>
          <population>Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.439" spread="7.350"/>
                    <measurement group_id="O2" value="23.10" spread="2.809"/>
                    <measurement group_id="O3" value="20.81" spread="5.384"/>
                    <measurement group_id="O4" value="18.86" spread="3.959"/>
                    <measurement group_id="O5" value="19.29" spread="5.468"/>
                    <measurement group_id="O6" value="15.96" spread="2.789"/>
                    <measurement group_id="O8" value="14.20" spread="5.521"/>
                    <measurement group_id="O9" value="12.89" spread="2.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of informed consent up to 14 (±2) days after the last dose of investigational product (IP). Treatment-emergent adverse events were those reported after the first dose of IP up to 14 (±2) days after the last dose of IP. Unresolved AEs were followed up by the investigator for as long as medically indicated.</time_frame>
      <desc>The Safety population comprised all randomised subjects who received at least 1 dose of the IP.</desc>
      <group_list>
        <group group_id="E1">
          <title>AZD8871 50 μg (Part 1)</title>
          <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
        </group>
        <group group_id="E2">
          <title>AZD8871 200 μg (Part 1)</title>
          <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
        </group>
        <group group_id="E3">
          <title>AZD8871 400 μg (Part 1)</title>
          <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
        </group>
        <group group_id="E4">
          <title>AZD8871 900 μg (Part 1)</title>
          <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
        </group>
        <group group_id="E5">
          <title>AZD8871 1800 μg (Part 1)</title>
          <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
        </group>
        <group group_id="E6">
          <title>AZD8871 2100 μg (Part 1)</title>
          <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
        </group>
        <group group_id="E7">
          <title>Placebo (Part 1)</title>
          <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
        </group>
        <group group_id="E8">
          <title>AZD8871 400 μg (Part 2)</title>
          <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
        </group>
        <group group_id="E9">
          <title>AZD8871 1800 μg (Part 2)</title>
          <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
        </group>
        <group group_id="E10">
          <title>Indacaterol 150 μg (Part 2)</title>
          <description>Single-dose, oral inhalation by Onbrez Breezhaler® single-dose dry powder inhaler (DPI)</description>
        </group>
        <group group_id="E11">
          <title>Tiotropium 18 μg (Part 2)</title>
          <description>Single-dose, oral inhalation by HandiHaler® single-dose dry powder inhaler (DPI)</description>
        </group>
        <group group_id="E12">
          <title>Placebo (Part 2)</title>
          <description>Single-dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E11" events="7" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E12" events="7" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of the results by the Principal Investigator (PI) will be subject to mutual agreement between the PI and the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

